Antivirals Study Experience

PPD is a leader in global HIV therapeutic development and has helped clients conduct more than 100 trials on six continents. In the past five years, we have conducted Phase I-IV studies involving hepatitis B and C, human papilloma virus and parainfluenza virus type 3, with more than 2,900 sites and 40,000 patients enrolled.¹ Our global investigator network and strong relationships ensure we secure the highest performing sites with the right patients for our clients’ programs.

1. These numbers don't include our work in the government sector, which is tracked separately.